SCHEMBL4160389

SCHEMBL4160389

N#CCC(=O)c1ccc2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.61
CES2 O00748 1/20 0.60
CES1 P23141 1/20 0.60
HPGD P15428 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
KDM4E B2RXH2 3/20 0.56
ALDH1A1 P00352 3/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 2/20 0.53
HDAC1 Q13547 2/20 0.49
HDAC8 Q9BY41 1/20 0.49
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 2/20 0.47
EGFR P00533 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29886728 1.00 PTPN1 (0.61) PTPN1CES2CES1HPGDSMN1; SMN2
SCHEMBL30238599 0.86 KDM4E (0.47) PTPN1CES2CES1HPGDSMN1; SMN2
SCHEMBL21694387 0.86 KDM4E (0.47) PTPN1CES2CES1HPGDSMN1; SMN2
SCHEMBL8533379 0.83 SMN1; SMN2 (0.61) PTPN1CES2CES1HPGDSMN1; SMN2
SCHEMBL30237946 0.80 PTPN11 (0.50) HPGDSMN1; SMN2KDM4EALDH1A1NPC1
SCHEMBL21694382 0.80 PTPN11 (0.50) HPGDSMN1; SMN2KDM4EALDH1A1NPC1
SCHEMBL1857883 0.80 CYP1A2 (0.61) CES2CES1HPGDSMN1; SMN2KDM4E
SCHEMBL11946959 0.79 PTPN1 (0.57) PTPN1CES2CES1HPGDSMN1; SMN2
SCHEMBL1519941 0.79 SMYD3 (0.44) KDM4EHDAC1CYP3A4
SCHEMBL397191 0.79 GSK3B (0.50) CES2CES1HPGDSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115974721-B Method for synthesizing 2-carbonyl substituted nitrile compound through 2, 2-trifluoroethyl ketone 平顶山学院 2024-07-02 CN claimed
CN-115974721-A Method for synthesizing 2-carbonyl substituted nitrile compound through 2,2,2-trifluoroethyl ketone 平顶山学院 2023-04-18 CN claimed
CN-115974721-B Method for synthesizing 2-carbonyl substituted nitrile compound through 2, 2-trifluoroethyl ketone 平顶山学院 2024-07-02 CN disclosed
WO-2023210772-A1 PHOTOELECTRIC CONVERSION ELEMENT, IMAGING ELEMENT, PHOTOSENSOR, AND COMPOUND 富士フイルム株式会社 2023-11-02 WO disclosed
CN-115974721-A Method for synthesizing 2-carbonyl substituted nitrile compound through 2,2,2-trifluoroethyl ketone 平顶山学院 2023-04-18 CN disclosed
US-11578071-B2 Preparation of pyrazolo[3,4-B]pyridines as antimalarials UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2023-02-14 US disclosed
CN-110272400-B Synthesis method of 2-trifluoromethyl substituted furan compound and derivative thereof 福州大学 2022-08-23 CN disclosed
CN-107024834-B Compound and coloring composition 住友化学株式会社 2021-11-23 CN disclosed
US-20210101901-A1 PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS CAL POLY CORPORATION 2021-04-08 US disclosed
WO-2021067967-A1 PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2021-04-08 WO disclosed
CN-107586469-B Pigment composition, coloring composition, and coloring curable composition 住友化学株式会社 2021-04-06 CN disclosed
EP-1401441-A2 ALLOSTERIC ADENOSINE RECEPTOR MODULATORS King Pharmaceuticals Research and Development Inc. (US) 2004-03-31 EP disclosed
US-20020147231-A1 Allosteric adenosine receptor modulators KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. 2002-10-10 US disclosed
US-20020147185-A1 Allosteric adenosine receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2002-10-10 US disclosed
US-20020143004-A1 Allosteric adenosine receptor modulators KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. 2002-10-03 US disclosed
WO-2002074056-A2 ALLOSTERIC ADENOSINE RECEPTOR MODULATORS KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC. (US) 2002-09-26 WO disclosed
US-20010047008-A1 Allosteric adenosine receptor modulators KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2001-11-29 US disclosed
EP-0491137-B1 Synthesis of 2-aryl-5-(trifluoromethyl)pyrroles useful as pesticidal agents and as intermediates for the preparation of said agents AMERICAN CYANAMID CO (US) 1995-12-27 EP disclosed
US-5128485-A SYNTHESIS OF 2-ARYL-5-(TRIFLUOROMETHYL)PYRROLES USEFUL AS PESTICIDAL AGENTS AND AS INTERMEDIATES FOR THE PREPARATION OF SAID AGENTS AMERICAN CYANAMID COMPANY (US) 1992-07-07 US disclosed
EP-0491137-A2 Synthesis of 2-aryl-5-(trifluoromethyl)pyrroles useful as pesticidal agents and as intermediates for the preparation of said agents AMERICAN CYANAMID COMPANY (US) 1992-06-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147231-A1 Allosteric adenosine receptor modulators ADORA2A, ADORA1, ADORA2B PTPN1 2249/4885CES2 3503/4885CES1 2309/4885
US-20210101901-A1 PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS PNPO, NOX3, G6PD PTPN1 1651/4885CES2 3291/4885CES1 2620/4885
US-11578071-B2 Preparation of pyrazolo[3,4-B]pyridines as antimalarials PNPO, NOX3, G6PD PTPN1 1651/4885CES2 3291/4885CES1 2620/4885
US-20010047008-A1 Allosteric adenosine receptor modulators ADORA2A, ADORA1, ADORA2B PTPN1 2097/4885CES2 3038/4885CES1 1781/4885
US-20020143004-A1 Allosteric adenosine receptor modulators ADORA2A, ADORA1, ADORA2B PTPN1 1935/4885CES2 3544/4885CES1 2118/4885
US-20020147185-A1 Allosteric adenosine receptor modulators ADORA2A, ADORA1, ADORA2B PTPN1 1935/4885CES2 3544/4885CES1 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.